论文部分内容阅读
美国血液学会(ASH)日前颁发了本届欧尼斯特·博特勒奖,获奖人员为来自上海某研究所的一位教授及其研究团队,以表彰他们在急性早幼粒细胞白血病(APL)基础和临床研究中所取得的突出成就。据悉,A P L曾是一种极为凶险、死亡率很高的恶性血液疾病。该研究团队应用全反式维甲酸(ATRA)和三氧化二砷(ATO)对APL进行联合靶向治疗,使得这一疾病的5年无病生存率跃升至90%以上,达到基本“治愈”标准。同时,从分子机制上揭示了ATRA和砷剂是如何分别作用于APL致病分子PML/
The American Institute of Hematology (ASH) recently presented the Ornister Bertre Award, a winner of a professor and research team from a Shanghai-based research institute in recognition of their role in acute promyelocytic leukemia (APL) Outstanding achievements in basic and clinical research. It is reported, APL was once a very dangerous, high mortality rate of hematological malignancies. The team used a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to target APL, bringing the 5-year disease-free survival rate of the disease to more than 90%, up to basic “cure” standards . At the same time, the molecular mechanism revealed how ATRA and arsenic act on APL pathogenic molecules PML /